Vibegron for ENergy Thinking and Resilience in Aging
Key claim: A 12-week randomized, double-blind, placebo-controlled trial will test whether vibegron (GEMTESA) improves energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Abstract
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Why this matters
Vibegron is an already-approved overactive-bladder drug being repositioned into the longevity space via a trial that measures energy metabolism, cardiometabolic risk, and physical and cognitive function — endpoints normally associated with GLP-1s or exercise mimetics. It is the second β3-adrenergic agonist (after mirabegron) to be formally probed for aging-adjacent outcomes, testing whether brown-fat activation translates into measurable healthspan signals in humans. Until readout, this is a trial launch, not a result.